Maryland Pharmacy Program

Volume 3, Number 3 October 2005

harmacy Pharmacy Volume News and Views

Updates to the Preferred Drug List (PDL)

The following six drug classes have been added to the Maryland Preferred Drug List effective on or about October 1, 2005:

- Alzheimers' Agents
- Anti-Parkinsons' Agents
- Atopic Dermatitis

Ophthalmics, Glaucoma Agents

- Hypoglycemics, Metformins
- Platelet Aggregation Inhibitors

The entire Preferred Drug List (PDL) is included as part of this newsletter. Changes to the PDL are highlighted. One major change is creating tiered therapy in the Stimulants and Related Agents Category. Effective on or about October 1, 2005, Strattera[®] will become a Tier Two product on the PDL. If there is no history of use of Strattera[®] or a Tier One agent in the recipient's most recent 90-day drug history, Strattera[®] will require a preauthorization. The preauthorization phone number is 800-932-3918. However, Strattera[®] may be adjudicated without a preauthorization based upon the following two exceptions:

- 1. Strattera[®] is considered a mental health drug, and therefore, grandfathered for all recipients who are currently receiving it.
- If a claim for Strattera[®] is submitted and the recipient has had a history of receiving a Tier One Agent within the previous 90-day period, it will adjudicate without a preauthorization.

Atypical Antipsychotic Agents

Atypical antipsychotic agents are widely prescribed and have dramatically improved the quality of life for many patients. However, these drugs are very costly and represent approximately 20% of the entire annual prescription drug budget for the Maryland Medicaid Program or nearly \$100 million of the \$500 million budget. In the past year, Maryland Medicaid has undertaken several initiatives focused on the appropriate utilization of atypical antipsychotic agents.

Dose optimization limits were implemented at the beginning of the year. More recently, an education letter was sent to the top 500 Maryland prescribers of atypical antipsychotic agents. The Department's goal is to ensure that Medicaid patients receive optimal drug therapy at the lowest reasonable cost. The letter listed the monthly cost of therapy for several widely used dosage regimens of the atypical agents and also listed several initiatives that can be taken

Pharmacy News and Views is on the Web

A copy of this newsletter and the previous editions of the *Pharmacy News and Views* newsletter can now be found on the HealthChoice Managed Care Organization website at www.mdmahealthchoicerx.com, under the Provider Information tab.

to promote the most cost-effective use of these agents. These initiatives include the following:

• Use of cost effective dosing for these agents based on current dose optimization limits.

• Combination of two antipsychotic agents should only be prescribed after an adequate trial of each agent prescribed individually at a maximum tolerated dose.

• Use of clozapine should be considered prior to initiating combination anti-psychotic therapy.

• Use of mood stabilizers and other non-antipsychotic augmentation strategies should be tried prior to initiation of combination antipsychotic therapy when mood symptoms are present.

• Limit the use of low doses of these agents when used strictly for their sedative effects and not for the treatment of psychosis or bi-polar disorders.

Ŗ

• For noncompliant patients, consider trial of long-acting antipsychotic agents (fluphenazine decanoate, haloperidol decanoate or Risperdal® Consta®).

• Monitor patients for development of hyperglycemia or worsening diabetes and adequately address treatment of these complications. (*continued page 2*)

Contents

 Updates to the Preferred Drug List
 1

 Atypical Antipsychotic Agents
 1

 Medicare Part D Coverage
 2

 Maryland Preferred Drug List
 3

 Revised Quantity Limits for Emend®
 8



Maryland Department of Health and Mental Hygiene, Office of Operations, Eligibility and Pharmacy

(continued from page 1)

Within the last several weeks, prescribers of patients taking at least three concurrent antipsychotic agents were identified and sent an educational letter as part of the Retrospective Drug Utilization Review (DUR) Program. A total of 574 patients were identified as taking a combination of at least three concurrent antipsychotic agents.

The Department is dedicated to improving the health and well being of our patients. We thank you for your participation in the Maryland Medicaid Program and hope that you will assist us in making the most effective utilization of our resources as we continue to provide valuable pharmacy benefits to our patients.

Medicare Part D Coverage

All Medicare beneficiaries will be eligible for prescription drug coverage. Those who are also eligible for Medicaid or those whose incomes fall below 135% of the Federal Poverty Level (FPL) are exempt from many of the requirements such as monthly premiums and deductibles, and are also not subject to any "gap" in coverage. Individuals with incomes between 135% and 150% of the FPL will pay a reduced premium, based on income, and have a \$50 annual deductible. Dual eligible patients who reside in long term care facilities pay no premiums or co-payments. The chart below shows the various copayment, premiums and deductibles.

Dual eligible Medicaid recipients who have not made a decision will be automatically enrolled in a PDP by CMS before the first of the year. Pharmacy Assistance recipients who have not done so will be automatically enrolled by DHMH. Enrollment by both CMS and DHMH will be random; however, DHMH will try to enroll husbands and wives into the same plan. Individuals who are not pleased with the PDP they were automatically enrolled in may change to a difference PDP. Pharmacy Discount Program recipients must enroll in a PDP on their own or else risk loss of prescription drug benefits. Those who do not enroll by May 15, 2006 will incur an ongoing penalty of one percent for every month they fail to enroll.

Dual Eligible Patients and Coverage of Drugs Not Covered Under Medicare Part D

As of January 1, 2006 the new Medicare Part D prescription drug plan will be implemented. Patient enrollment in the Prescription Drug Plans (PDPs) begins November 15, 2005. There are 34 PDP regions throughout the country. Maryland, Delaware and the District of Columbia encompass our local region. During the month of October, the Centers for Medicare and Medicaid Services (CMS) will be sending all eligible Medicare beneficiaries a handbook with instructions on how to enroll in one of the PDPs. Please assist your patients in whatever way you can to facilitate the enrollment process. The CMS website www.medicare.gov is being updated on a regular

basis with patient information brochures and answers to frequently asked questions. Patients who are currently dual eligible to receive both Medicare and Medicaid benefits will be automatically enrolled in one of the Medicare PDPs.

These patients will no longer receive their prescription benefits from Medicaid. Their drug benefits must be obtained through Medicare with only a few exceptions. The PDPs are not required to cover the following drug classes, which are excluded under Part D:

- Benzodiazepines
- Barbiturates
- Over The Counter (OTC) Drugs
- Cough and Cold Medications
- Fertility Agents
- Weight Loss Agents

At this time the drug formularies for the PDPs are not known. Some of the PDPs may cover some of the excluded drugs, such as benzodiazepines and barbiturates. If the PDPs do not cover benzodiazepines and barbiturates, then Maryland Medicaid will cover these and other excluded drugs that are normally covered for other Medicaid recipients, but only for patients who are dual eligible and have full Medicaid benefits.

Ŗ

Medicare Part D Cost Sharing

Beneficiary Income	Part D Premium	Deductible	Co-Payment	Coverage Gap
Up to 100% FPL*	None	None	\$1 Generic, \$3 Brand	None
Up to 135% FPL	None	None	\$2 Generic, \$5 Brand	None
Up to 150% FPL	Sliding scale based on income	\$50 e	15%	None

* Federal Poverty Level for the purpose of Medicare Part D is \$12,919 or less (if single) or \$17,320 or less (if married) with assets less than \$6,000 (single) or \$9,000 (married).

Only drugs that are part of the listed therapeutic categories are affected by the PDL. Therapeutic categories not listed here are not part of the PDL and will continue to be covered as they always have for Maryland Medicaid patients.

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred. PDL products that are new to market require prior autorization until they are reviewed. Key: All lowercase letters = generic product; Leading capital letter = brand name product; Effective October 1, 2005

ANALGESIC

Analgesics, Narcotics

Preferred

acetaminophen w/codeine (Tylenol w/Codeine) aspirin w/codeine (Empirin w/Codeine) butalbital/apap/codeine butalbital/apap/codeine/caffeine codeine hydrocodone/apap (Vicodin) hydrocodone/ibuprofen (Vicoprofen) hydromorphone (Dilaudid) morphine sulfate morphine sulfate SR (MS Contin) oxycodone oxycodone/apap (Percocet) oxycodone/aspirin (Percodan) pentazocine/apap (Talacen) pentazoncine/naloxone (Talwin NX) propoxyphene (Darvon) propoxyphene HCI/apap (Wygesic) propoxyphene napsylate/apap (Darvocet) tramadol (Ultram) tramadol/acetaminophen (Ultracet) Duragesic (brand only) Kadian

 Requires Prior Authorization

 fentanyl patch (generic only)

 meperidine (Demerol) (brand &

 generic only)

 oxycodone ER (brand & generic only)

 Actiq

 Avinza

 Combunox

 Darvon-N

 Synalgos-DC

 Panlor DC, SS

Anti-Migrane Agents, Triptans (Anti-Migraine Preparations)

<u>Preferred</u>

Axert Maxalt, Maxalt MLT Zomig, Zomig Nasal, Zomig ZMT

<u>Requires Prior Authorization</u> Amerge Frova Imitrex (oral, nasal & subq) Relpax

ANALGESIC

Nonsteroidal Anti-Inflammatories/ COX II Inhibitor (NSAIDS, Cyclooxygenase Inhibitor - Type)

Preferred FIRST TIER: diclofenac potassium (Cataflam) diclofenac sodium, diclofenac sodium XL (Voltaren, XR) etodolac, etodolac XL (Lodine, Lodine XL) fenoprofen (Nalfon) flurbiprofen (Ansaid) ibuprofen (Motrin) indomethacin, indomethacin SR (Indocin, Indocin SR) ketoprofen (Orudis, Oruvail) ketorolac (Toradol) meclofenamate (Meclomen) nabumetone (Relafen) naproxen (Naprosyn) naproxen sodium, naproxen sodium DS (Anaprox, Anaprox DS) oxaprozin (Daypro) piroxicam (Feldene) sulindac (Clinoril) tolmetin, tolmetin DS (Tolectin, Tolectin DS) SECOND TIER: Celebrex Prevacid NapraPac

<u>Requires Prior Authorization</u> Arthrotec Mobic Ponstel

ANTI-INFECTIVES

Antifungals, Oral (Antifungal Agents, Antifungal Antibiotics)

<u>Preferred</u> clotrimazole troche (Mycelex) fluconazole (Diflucan) griseofulvin (Fulvicin, GriFulvin V) itraconazole (Sporanox) ketoconazole (Nizoral) nystatin Gris Peg Lamisil Mycostatin Pastilles

<u>Requires Prior Authorization</u> Ancobon Sporanox Solution Vfend

ANTI-INFECTIVES

Antifungals, Topical (Topical Antifungals)

<u>Preferred</u> ciclopirox lotion (Loprox) clotrimazole (Lotrimin) clotrimazole/betamethasone (Lotrisone) econazole (Spectazole) ketoconazole (Nizoral) nystatin (Mycostatin) nystatin/triamcinolone (Mycolog II)

Requires Prior Authorization

Ertaczo Mentax Naftin Oxistat Penlac

Antivirals (Antivirals, General)

<u>Preferred</u>

acyclovir (Zovirax) amantadine (Symmetrel) ganciclovir (Cytovene) rimantadine (Flumadine) Valcyte Valtrex

<u>Requires Prior Authorization</u> Famvir Relenza Tamiflu

Cephalosporin & Related Agents (Cephalosporins, Second & Third Generation, Penicillins)

<u>Preferred</u>

amoxiciliin/clavulanate (Augmentin, Augmentin ES) cefaclor (Ceclor, Ceclor CD) cefadroxil (Duricef) cefuroxime (Ceftin) cefpodoxime (Vantin) cephalexin (Keflex) Cedax Cefzil Omnicef Spectracef Suprax

<u>Requires Prior Authorization</u> Augmentin XR Lorabid Panixine Raniclor

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred. Key: All lowercase letters = generic product; Leading capital letter = brand name product; Effective October 1, 2005

ANTI-INFECTIVES

Fluoroquinolones (Quinolones)

<u>Preferred</u> ciprofloxacin (Cipro) ofloxacin (Floxin) Avelox

Requires Prior Authorization

Cipro XR Levaquin Maxaquin Noroxin Tequin

Macrolides/Ketolides

<u>Preferred</u>

clarithromycin (Biaxin) erythromycin Biaxin XL Zithromax

<u>Requires Prior Authorization</u> Branded erythromycin products Ketek

CARDIOVASCULAR

ACE Inhibitor/Calium Channel Blocker Combination

<u>Preferred</u> Lotrel Tarka

<u>Requires Prior Authorization</u> Lexxel

ACE Inhibitors (Hypotensives, ACE Inhibitors)

Preferred benazepril, benazepril HCTZ (Lotensin, Lotensin HCT) captopril, captopril HCTZ (Capoten, Capozide) enalapril. enalapril HCTZ (Vasotec. Vaseretic) fosinopril, fosinopril HCTZ (Monopril, Monopril HCT) lisinopril, lisinopril HCTZ (Prinivil, Zestril, Prinzide, Zestoretic) quinapril (Accupril) quinaretic (Accuretic) Altace Mavik Univasc/Uniretic

<u>Requires Prior Authorization</u> Aceon

CARDIOVASCULAR

Angiotensin Receptor Blockers (Hypotensives, Angiotensin Receptor Antagonist)

<u>Preferred</u> Avapro, Avalide Cozaar, Hyzaar Diovan, Diovan HCT Micardis, Micardis HCT

<u>Requires Prior Authorization</u> Atacand, Atacand HCT Benicar, Benicar HCT Teveten, Teveten HCT

Beta Blockers (Alpha/Beta-Adrenergic Blocking Agents, Beta-Adrenergic Blocking Agents)

Preferred

acebutolol (Sectral) atenolol (Tenormin) betaxolol (Kerlone) bisoprolol (Zebeta) labetalol (Normodyne, Trandate) metoprolol (Lopressor) nadolol (Corgard) pindolol (Visken) propranolol (Inderal) sotalol, sotalol AF (Betapace, Betapace AF) timolol (Blocadren) Inderal LA Innopran XL Toprol XL

<u>Requires Prior Authorization</u> Cartrol Coreg Levatol

Calcium Channel Blocking Agents

<u>Preferred</u> diltiazem (Cardizem) diltiazem SR, diltiazem ER (Cardizem SR, Cardizem CD, Dilacor XR, Tiazac) felodipine (Plendil) nicardipine (Cardene) nifedipine SR (Adalat CC, Procardia XL) verapamil (Calan) verapamil ER, verapamil SR (Calan SR, Verelan) Cardizem LA DynaCirc CR Sular Verelan PM **Requires Prior Authorization** nifedipine (Adalat, Procardia) Cardene SR Covera-HS Dynacirc IR

CARDIOVASCULAR

Lipotropics, Other (Lipotropics, Bile Salt Sequestrants)

<u>Preferred</u>

cholestyramine (Questran, Light) gemfibrozil (Lopid) niacin (Niacor) Colestid Niaspan Tricor

<u>Requires Prior Authorization</u> Antara Lofibra Welchol Zetia

Lipotropics, Statins (Lipotropics)

<u>Preferred</u> lovastatin (Mevacor) Advicor Altoprev Crestor Lescol, XL Vytorin Zocor

<u>Requires Prior Authorization</u> Caduet Lipitor Pravachol Pravigard PAC

Platelet Aggregation Inhibitors

<u>Preferred</u> dipyridamole (Persantine) ticlopidine (Ticlid) Aggrenox Plavix

Requires Prior Authorization

Nimotop

Norvasc

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred. Key: All lowercase letters = generic product; Leading capital letter = brand name product; Effective October 1, 2005

CENTRAL NERVOUS SYSTEM

Antidepressants, Other (Alpha-2 Receptor Antagonist Antidepressants, Serotonin-2 Antagonist/Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake-Inhib, Norepinephrine & Dopamine Reuptake Inhib)

Preferred

bupropion, bupropion SR (Wellbutrin, Wellbutrin SR) mirtazapine, mirtazapine soltab (Remeron, Remeron Soltab) trazodone (Desyrel) Effexor, Effexor XR

<u>Requires Prior Authorization</u> nefazodone (Serzone) Cymbalta Wellbutrin XL

Sedative Hypnotics

<u>Preferred</u>

chloral hydrate estazolam (ProSom) flurazepam (Dalmane) temazepam (Restoril) triazolam (Halcion) Restoril 7.5mg Sonata

<u>Requires Prior Authorization</u> Ambien Doral Lunesta Restoril 22.5mg

Selective Serotonin Reuptake Inhibitors (SSRIs)

<u>Preferred</u>

citalopram (Celexa) fluoxetine (Prozac) fluvoxamine (Luvox) paroxetine (Paxil) Lexapro Paxil CR Pexeva

Requires Prior Authorization

Prozac Weekly Sarafem Symbyax Zoloft

CENTRAL NERVOUS SYSTEM

Stimulants & Related Agents (Tx for Attention Deficit Hyperact (ADHD)/Narcolepsy; Adrenergics, Aromatic, Non-Catecholamine)

<u>Preferred</u>

FIRST TIER: amphetamine salt combo (Adderall) dextroamphetamine (Dexedrine) methylphenidate (Ritalin) methylphenidate ER (Metadate ER, Ritalin-SR) permoline (Cylert) Adderall XR Concerta Focalin, Focalin XR Metadate CD Ritalin LA SECOND TIER: Strattera

<u>Requires Prior Authorization</u> Desoxyn

ENDOCRINE

Bone Resorption Suppression & Related Agents (Bone Resorption Inhibitors, Bone Formation Stim. Agents - Parathyroid Hormone)

<u>Preferred</u> Actonel Fosamax, Fosamax Plus D Miacalcin

<u>Requires Prior Authorization</u> Boniva Didronel Evista

Estrogen Agents, Combination (Estrogenic Agents)

<u>Preferred</u> Activella CombiPatch FemHRT Prefest Premphase Prempro

<u>Requires Prior Authorization</u> Climara Pro

ENDOCRINE

Hypoglycemics, Insulins & Related Agents

Preferred Byetta Lantus Novolin Novolog Novolog Mix Symlin

<u>Requires Prior Authorization</u> Humulin Humalog Humalog Mix

Hypoglycemics, Meglitinides (Hypoglycemics, Insulin Release Stimulant Type)

<u>Preferred</u> Starlix

<u>Requires Prior Authorization</u> Prandin

Hypoglycemics, Metformins

<u>Preferred</u> glyburide/metformin (Glucovance) metformin (Glucophage) metformin XR (Glucophage XR) avandamet Fortamet Riomet

<u>Requires Prior Authorization</u> Metaglip

Hypoglycemics, TZDs (Hypoglycemics, Insulin-Response Enhancers)

<u>Preferred</u> Actos

<u>Requires Prior Authorization</u> Avandia

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred. Key: All lowercase letters = generic product; Leading capital letter = brand name product; Effective October 1, 2005

GASTROINTESTINAL

Antiemetics, Oral (Antiemetic/Antivertigo Agents)

<u>Preferred</u> Emend Zofran, Zofran ODT

<u>Requires Prior Authorization</u> Anzemet Kytril

Phosphate Binders & Related Agents

<u>Preferred</u> Magnebind RX PhosLo

<u>Requires Prior Authorization</u> Fosrenol Renagel

Proton Pump Inhibitors (Gastric Acid Secretion Reducers)

<u>Preferred</u> Prevacid Prilosec OTC

Requires Prior Authorization

omeprazole Aciphex Nexium Protonix Zegerid

Ulcerative Colitis Agents

<u>Preferred</u> sulfasalazine (Azulfidine) mesalamine enemas (Rowasa) Colazal Pentasa

<u>Requires Prior Authorization</u> Asacol Canasa Dipentum

INJECTABLE

Anticoagulants, Injectable

Preferred Fragmin Lovenox

<u>Requires Prior Authorization</u> Arixtra Innohep

INJECTABLE

Cytokine & CAM Antagonists (AntiInflammatory, Pyrimidine Synthesis Inhibitor, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor, Anti-Flam, Interleukin-1 Receptor Antagonist, Drugs to Tx Chronic Inflamm Disease of Colon, Antimetabolites)

<u>Preferred</u> Enbrel Humira Kineret Raptiva

<u>Requires Prior Authorization</u> Amevive

Erythropoietins (Hematinics, Other)

<u>Preferred</u> Aranesp Procrit

<u>Requires Prior Authorization</u> Epogen

Growth Hormones (CLINICAL PA REQUIRED)

<u>Preferred</u> Norditropin Nutropin AQ Tev-Tropin

Requires Prior Authorization

Génotropin Humatrope Nutropin Saizen Serostim

* Nutropin Depot is available by the manufacturer only to those patients on existing therapy.

Hepatitis C Agents (Hepatitis C Treatment Agents, Immunomodulators)

<u>Preferred</u> Peg-Intron Peg-Intron Redipen Rebetol **(brand only)**

<u>Requires Prior Authorization</u> ribavirin (generic only) Copegus Infergen Pegasys Rebetron

Multiple Sclerosis Agents (Agents to Treat Multiple Sclerosis)

<u>Preferred</u> Avonex Betaseron Rebif

<u>Requires Prior Authorization</u> Copaxone

NEUROLOGICS

Alzheimer's Agents

<u>Preferred</u> Aricept/Aricept ODT Exelon Namenda Razadyne Razadyne ER

<u>Requires Prior Authorization</u> Cognex

Anti-Parkinson's Agents

<u>Preferred</u> benztropine (Cogentin) levodopa/carbidopa Immediate and Extended Release (Sinemet, Sinemet CR) pergolide (Permax) selegiline (Eldepryl) trihexyphenidyl (Artane) Comtan Kemadrin Mirapex Requip Stalevo

<u>Requires Prior Authorization</u> Parcopa Tasmar

OPHTHALMIC

Ophthalmics, Allergic Conjunctivitis (Eye AntiInflammatory Agents, Eye Antihistamines, Ophthalmic Mast Cell Stabilizers)

<u>Preferred</u> cromolyn (Opticrom) Acular Alrex Elestat Patanol

<u>Requires Prior Authorization</u> Alamast

Alocril Alomide Emadine Optivar Zaditor

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred. Key: All lowercase letters = generic product; Leading capital letter = brand name product; Effective October 1, 2005

OPHTHALMIC

Ophthalmics, Antibiotics

<u>Preferred</u>

bacitracin ciprofloxacin solution (Ciloxan) erythromycin (Ilotycin) gentamicin (Garamycin) ofloxacin (Ocuflox) tobramycin (Tobrex) Zymar

<u>Requires Prior Authorization</u> Ciloxan ointment Vigamox Quixin

Ophthalmics, Glaucoma Agents

<u>Preferred</u>

betaxolol brimonidine carteolol (Ocupress) dipivefrin (Propine) levobunolol (Betagan) metipranolol (OptiPranolol) pilocarpine (Pilocar) timolol (Timoptic, Timoptic XE) Alphagan P Azopt Betimol betoptic S Cosopt Lumigan Travatan Trusopt

<u>Requires Prior Authorization</u> Istalol Xalatan

OTIC

Otics, Antibiotics (Ear Preparations, Antibiotics; Otic Preparations, Anti-Inflammatory-Antibiotics)

Preferred

neomycin/polymyxin/hydrocortisone (Cortisporin) Ciprodex Coly-Mycin S Floxin Otic

<u>Requires Prior Authorization</u> Cipro HC Cortisporin-TC

RESPIRATORY

Antihistamines, Minimally Sedating (Antihistamines)

<u>Preferred</u> loratadine, loratadine-D (OTC) Alavert, Alavert-D (OTC) Claritin, Claritin-D (OTC) Tavist ND (OTC) Clarinex syrup

<u>Requires Prior Authorization</u> Allegra, Allegra-D Claritin, Claritin-D (Rx) Clarinex, Clarinex-D (tablets) Zyrtec, Zyrtec-D

Bronchodilators, Anticholinergics

Preferred

ipratropium neb (Atrovent) Atrovent HFA Combivent Spiriva

<u>Requires Prior Authorization</u> DuoNeb

Beta₂-Agonist Bronchodilators (Beta-Adrenergic Agents)

<u>Preferred</u> albuterol (Proventil, Ventolin) albuterol HFA (Proventil HFA, Ventolin HFA) metaproterenol (Alupent) terbutaline (Brethine) Maxair Serevent Diskus Xopenex

<u>Requires Prior Authorization</u> AccuNeb Alupent Foradil Vospire ER

Glucocorticoids, Inhaled (Beta-Adrenergics & Glucocorticoids Combination, Blucocorticoids)

<u>Preferred</u> Advair Diskus Aerobid, Aerobid M Azmacort Flovent HFA Pulmicort Respules (Ages 1-8) Qvar

<u>Requires Prior Authorization</u> Pulmicort Respules (Over Age 8, Under Age 1) Pulmicort Turbuhaler

RESPIRATORY

Intranasal Rhinitis Agents (Nasal Anti-Inflammatory Steriods)

<u>Preferred</u> flunisolide (Nasalide) ipratropium (Atrovent Nasal) Flonase Nasacort AQ Nasonex

<u>Requires Prior Authorization</u> Beconase AQ Nasarel Rhinocort Aqua

Leukotriene Receptor Antagonists

<u>Preferred</u> Accolate Singulair

Requires Prior Authorization

TOPICAL DERMATOLOGICS

Atopic Dermatitis

<u>Preferred</u> Elidel Protopic

Requires Prior Authorization

UROLOGIC

Benign Prostatic Hyperplasia (Alpha-Adrenergic Blocking Agents)

<u>Preferred</u> doxazosin (Cardura) terazosin (Hytrin) Flomax Proscar Uroxatral

<u>Requires Prior Authorization</u> Avodart

Bladder Relaxant Preparations (Urinary Tract Antispasmodic/ Antiincontinence Agent)

<u>Preferred</u> oxybutynin (Ditropan) Ditropan XL Enablex Oxytrol

<u>Requires Prior Authorization</u> Detrol Detrol LA Sanctura Vesicare

Pharmacy News and Views Maryland Department of Health and Mental Hygiene Office of Operations, Eligibility

and Pharmacy Maryland Pharmacy Program 201 West Preston St., 4th Floor Baltimore, Maryland 21201

410-767-1455

Robert L. Ehrlich, Jr., *Governor* Michael S. Steele, *Lt. Governor* S. Anthony McCann, *Secretary, DHMH*

Phil Cogan, R.Ph, *Editor* STAFF: Eva Carey-Brown Joseph Paradis, PharmD, of Health Information Designs, Inc.

Revised Quantity Limits for Emend®

In an effort to avoid wastage in the anti-emetic class of drugs, the Maryland Pharmacy Program has instituted quantity limitations that are explicit in the Food and Drug Administration labeling of these drugs. While the newer anti-emetics offer therapeutic advantages over their traditional counterparts, they are substantially more costly. Since they are indicated for only a few days post chemotherapy or radiation therapy, their use will be appropriately limited to quantities more reflective of anticipated treatment duration. When necessary, prior authorizations for quantities in

excess of these limits may be requested from the Maryland Pharmacy Program at 800-492-5231. Effective on or about October 1, 2005, the maximum allowable quantities for Emend[®] will be limited to the amounts listed in the following table of anti-emetic agents:

MAXIMUM QUANTITY LIMITS FOR EMEND®

Product preferred in bold)	Strengths / Dosage Forms	Approved Adjunct Chemo Regiments	30-Day Quantity Limits
(aprepitant)	125mg caps	Chemotherapy: 125 mg 1hour pre-	1 tab
	80mg caps	treatment, then 80mg daily for 2-3 days in combination with dexamethasone	2 tabs
	125mg / 80mg tri-fold pack (3's)		1 3-pack (total 3 tabs)
Marinol [®] (dronabinol)	2.5mg, 5mg and 10mg caps	Chemotherapy: 2.5 to 40mg per day in divided doses every 4-6 hours	60 caps
Zofran ODT [®] (ondanstron)	Zofran [®] 4mg and 8mg tabs - 30s, 100s, & 1x3 daily UD packs	Chemotherapy: 8mg, 30 min. pre-treatment and 8mg, 8 hours late; then 8mg q 12	15 tabs (4 or 8mg)
	Zofran [®] 24mg tabs - 1x1 daily UD packs	hours for 1-2 days post-treatment	10 tabs (4 or 8mg)
	Zofran [®] oral solution (4mg/5ml) - 50ml bottles	Radiation: 8mg, 1-2 hours pre-treatment;	100ml
		then up to q 8 hours for 1-2 days post- treatment	15 tabs (4 or 8mg)
Anzemet [®] (dolasetron)	50mg and 100mg tabs - 5s, blister pack 5s and UD 10s	Chemotherapy: 100mg within 1 hour of chemotherapy	10 tabs
(granicotron)	1mg tabs - 2s and 20s	Chemotherapy: 2mg q d within 1 hour of	15 tabs
	1mg/5ml oral solution - 30ml	treatment or 1mg (5ml) 1 hour prior to treatment and 1mg (5ml) 12 hours later Radiation: 2mg within 1 hour of treatment	90ml

All Program information and updates featured in this issue of *Pharmacy News and Views* are the best information available at the time of printing. Any updates that became effective after the date of printing will be included in the next issue of our newsletter.